Welcome to our dedicated page for Marex Group plc SEC filings (Ticker: MRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles U.S. Securities and Exchange Commission filings for Marex Group plc (NASDAQ: MRX), a diversified global financial services platform operating across energy, commodities and financial markets. As a foreign private issuer, Marex files an annual report on Form 20-F and periodic Form 6-K reports that furnish press releases and financial information to U.S. investors.
Recent Form 6-K filings include earnings-related disclosures, such as interim results, third quarter results and preliminary trading updates. These documents provide detail on revenue, adjusted profit before tax, segment performance across Clearing, Agency and Execution, Market Making, and Hedging and Investment Solutions, as well as information on net commission income, net trading income, net interest income and net physical commodities income. They also discuss non-IFRS measures, their definitions and reconciliations to the most comparable IFRS metrics.
Other 6-Ks relate to corporate actions and governance, including press releases about purchases of ordinary shares by the Chief Executive Officer and other directors and officers. These filings help investors track insider share dealings and understand how management and board members are building or adjusting their holdings in Marex.
Filings may also reference capital and ratings developments, such as senior debt issuances, Additional Tier 1 instruments and credit ratings from S&P Global Ratings for Marex Group and its U.S. subsidiary, Marex Capital Markets Inc. Together, these disclosures provide insight into the Group’s capital structure, funding and external credit assessment.
On Stock Titan, Marex’s SEC filings are updated as new documents are released on EDGAR. AI-powered tools can assist users by surfacing key points from lengthy filings, highlighting segment trends, explaining non-IFRS measures and drawing attention to notable items such as insider transactions and earnings commentary, helping readers navigate the technical language common in cross-border capital markets reporting.
MRX: a Form 144 notice lists proposed sales of Common Stock by an issuer insider.
The filing shows proposed sell quantities tied to compensation grants: 29,769 shares with a 03/10/2025 grant date and 7,374 shares with a 05/19/2025. The broker listed is J.P. Morgan Securities LLC.
Marex Group plc is offering Autocallable Fixed Income Notes with Absolute Return Buffer linked to the worst performing of AAPL, COHR and MS. Each Note has a $1,000 principal amount, quarterly fixed interest equal to 3.00% per quarter (12.00% per annum), an expected Estimated Initial Value between $920.00 and $960.00, a Final Valuation Date of December 13, 2027 and a Maturity Date of December 20, 2027.
The Notes pay quarterly interest and are subject to an automatic call if each Underlying is at or above its Call Threshold on a Call Observation Date. At maturity, payments depend on the Reference Return of the Worst Performing Underlying, a 50.00% Buffer Amount, and a Downside Leverage Factor of 200%, exposing holders to potential loss of up to 100% of principal (excluding final Interest Payment). The Notes are senior unsecured obligations of Marex and carry Marex credit risk.
Marex Group plc director Assi Georges reported an equity award. On June 9, 2026, he was granted 2,070 Ordinary Shares at a price of $0.00 per share as a restricted share award. The filing notes these awards are contingent rights that convert into one Ordinary Share each upon vesting and settlement, giving him 2,070 shares reported as directly owned after the grant.
Schweinitz Konstantin Graf von reported acquisition or exercise transactions in this Form 4 filing.
Marex Group plc director Schweinitz Konstantin Graf von received an equity grant of 2,070 restricted share awards, each representing a contingent right to one ordinary share upon vesting and settlement. Following this grant, he directly holds 26,165 ordinary shares of Marex Group plc.
Ing Sarah reported acquisition or exercise transactions in this Form 4 filing.
Marex Group plc director Ing Sarah reported a grant of 2,070 ordinary shares in the form of restricted share awards. The awards were granted at a price of 0.0000 per share and represent a contingent right to receive one ordinary share per award upon vesting and settlement.
Following this grant, Ing Sarah holds 10,895 ordinary shares directly and 535 ordinary shares indirectly through a spouse. The filing reflects a compensation-related share award rather than an open-market purchase or sale.
Pietrowicz John W. reported acquisition or exercise transactions in this Form 4 filing.
Marex Group plc director Pietrowicz John W. received a grant of 2,070 Ordinary Shares as a restricted share award. The shares were awarded at no cash cost and are subject to vesting and settlement conditions. Following this compensation-related award, he directly holds 23,771 Ordinary Shares in total.
Myers Linda Kristine reported acquisition or exercise transactions in this Form 4 filing.
Marex Group plc director Linda Kristine Myers reported receiving an equity grant of 2,070 restricted share awards of Ordinary Shares on June 9, 2026 at no cash cost per share. Each award is a contingent right to one ordinary share upon vesting and settlement. Following this grant, she directly holds 23,214 Ordinary Shares, reflecting routine share-based compensation rather than an open-market purchase.
Pickering Robert Mark reported acquisition or exercise transactions in this Form 4 filing.
Marex Group plc director Robert Mark Pickering received an equity grant of 2,070 ordinary shares in the form of restricted share awards. The grant was made at no cash cost per share and increases his direct holdings to 31,766 ordinary shares, including the unvested awards that will deliver one share per award upon vesting.
Marex Group plc has completed an offering of U.S.$500 million perpetual subordinated resettable fixed rate notes, described as hybrid perpetual securities. The notes are expected to receive 100% equity credit from S&P following Marex’s proposed Bermuda redomiciliation.
Marex intends to use the net proceeds for general corporate purposes, including funding the purchase of any or all of its outstanding U.S.$100,000,000 13.250% fixed rate reset perpetual subordinated contingent convertible notes via a tender offer announced on 1 June 2026 and for acquisitions. The new notes are priced at 7.7%, compared to the previous AT1 issuance at 13.25%, which management highlights as evidence of progress and investor confidence.
Marex Group plc submitted an SEC insider filing for director Assi Georges. The provided data shows no reported transactions in company securities and no listed derivative positions or holdings, indicating this filing is purely informational with respect to this insider’s status.